Intensity Therapeutics Common Net Income
| INTS Stock | 0.37 0.02 5.13% |
As of the 13th of February 2026, Intensity Therapeutics retains the Market Risk Adjusted Performance of (0.05), standard deviation of 6.92, and insignificant Risk Adjusted Performance. Intensity Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Intensity Therapeutics risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Intensity Therapeutics is priced fairly, providing market reflects its last-minute price of 0.37 per share. As Intensity Therapeutics appears to be a penny stock we also urge to confirm its jensen alpha numbers.
Intensity Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Intensity Therapeutics' valuation are provided below:There are over one hundred nineteen available fundamental trends for Intensity Therapeutics, which can be analyzed over time and compared to other ratios. All traders should confirm Intensity Therapeutics' regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 26.7 M in 2026. Enterprise Value is likely to drop to about 24.1 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -14.6 M | -13.9 M | |
| Net Loss | -7.1 M | -7.5 M | |
| Net Loss | -14.6 M | -13.9 M | |
| Net Loss | (1.35) | (1.41) | |
| Net Income Per E B T | 0.90 | 0.79 |
Intensity | Net Income | Build AI portfolio with Intensity Stock |
The evolution of Net Income for Intensity Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Intensity Therapeutics compares to historical norms and industry peers.
Latest Intensity Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Intensity Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Intensity Therapeutics financial statement analysis. It represents the amount of money remaining after all of Intensity Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Intensity Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intensity Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (16.27 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Intensity Net Income Regression Statistics
| Arithmetic Mean | (7,592,888) | |
| Coefficient Of Variation | (50.17) | |
| Mean Deviation | 2,974,693 | |
| Median | (5,229,129) | |
| Standard Deviation | 3,809,089 | |
| Sample Variance | 14.5T | |
| Range | 11M | |
| R-Value | (0.80) | |
| Mean Square Error | 5.5T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (605,294) | |
| Total Sum of Squares | 232.1T |
Intensity Net Income History
Other Fundumenentals of Intensity Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Intensity Therapeutics Net Income component correlations
Intensity Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Intensity Therapeutics is extremely important. It helps to project a fair market value of Intensity Stock properly, considering its historical fundamentals such as Net Income. Since Intensity Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intensity Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intensity Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Intensity introduce new products? Factors like these will boost the valuation of Intensity Therapeutics. Market participants price Intensity higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Intensity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intensity Therapeutics is measured differently than its book value, which is the value of Intensity that is recorded on the company's balance sheet. Investors also form their own opinion of Intensity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intensity Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Intensity Therapeutics' market value can be influenced by many factors that don't directly affect Intensity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intensity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intensity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Intensity Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Intensity Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Intensity Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Intensity Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Intensity Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Intensity Therapeutics Common or generate 0.0% return on investment in Intensity Therapeutics over 90 days. Intensity Therapeutics is related to or competes with Iterum Therapeutics, Rallybio Corp, IBio Common, Pluri, Boundless Bio, Plus Therapeutics, and NextCure. Intensity Therapeutics is entity of United States More
Intensity Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Intensity Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Intensity Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (8.70) | |||
| Potential Upside | 11.43 |
Intensity Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intensity Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Intensity Therapeutics' standard deviation. In reality, there are many statistical measures that can use Intensity Therapeutics historical prices to predict the future Intensity Therapeutics' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.72) | |||
| Treynor Ratio | (0.06) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Intensity Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intensity Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 4.49 | |||
| Coefficient Of Variation | (6,753) | |||
| Standard Deviation | 6.92 | |||
| Variance | 47.85 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.72) | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (8.70) | |||
| Potential Upside | 11.43 | |||
| Skewness | 1.21 | |||
| Kurtosis | 5.97 |
Intensity Therapeutics Backtested Returns
Intensity Therapeutics holds Efficiency (Sharpe) Ratio of close to zero, which attests that the entity had a close to zero % return per unit of risk over the last 3 months. Intensity Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Intensity Therapeutics' insignificant Risk Adjusted Performance, standard deviation of 6.92, and Market Risk Adjusted Performance of (0.05) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.99, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intensity Therapeutics will likely underperform. At this point, Intensity Therapeutics has a negative expected return of -0.011%. Please make sure to check out Intensity Therapeutics' treynor ratio and daily balance of power , to decide if Intensity Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.07 |
Virtually no predictability
Intensity Therapeutics Common has virtually no predictability. Overlapping area represents the amount of predictability between Intensity Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Intensity Therapeutics price movement. The serial correlation of 0.07 indicates that barely 7.0% of current Intensity Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.07 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Intensity Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Intensity Therapeutics Common reported net income of (16.27 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
Intensity Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intensity Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intensity Therapeutics could also be used in its relative valuation, which is a method of valuing Intensity Therapeutics by comparing valuation metrics of similar companies.Intensity Therapeutics is currently under evaluation in net income category among its peers.
Intensity Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Intensity Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Intensity Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intensity Therapeutics' value.| Shares | Xtx Topco Ltd | 2025-06-30 | 24.6 K | Qtr Family Wealth, Llc | 2025-06-30 | 17.4 K | Stonebridge Financial Group, Llc | 2025-06-30 | 16.5 K | Ewa, Llc | 2025-06-30 | 16 K | Boothbay Fund Management, Llc | 2025-06-30 | 15 K | State Street Corp | 2025-06-30 | 14.5 K | Northern Trust Corp | 2025-06-30 | 14 K | Virtu Financial Llc | 2025-06-30 | 13.7 K | Tower Research Capital Llc | 2025-06-30 | 13.5 K | Sentinus, Llc | 2025-06-30 | 199.3 K | Brown Advisory Holdings Inc | 2025-06-30 | 130.1 K |
Intensity Fundamentals
| Return On Equity | -2.35 | ||||
| Return On Asset | -1.02 | ||||
| Current Valuation | 15.52 M | ||||
| Shares Outstanding | 60.06 M | ||||
| Shares Owned By Insiders | 8.79 % | ||||
| Shares Owned By Institutions | 7.59 % | ||||
| Number Of Shares Shorted | 1.16 M | ||||
| Price To Book | 3.11 X | ||||
| EBITDA | (16.27 M) | ||||
| Net Income | (16.27 M) | ||||
| Total Debt | 138 K | ||||
| Book Value Per Share | 0.15 X | ||||
| Cash Flow From Operations | (15.22 M) | ||||
| Short Ratio | 0.92 X | ||||
| Earnings Per Share | (0.55) X | ||||
| Target Price | 2.9 | ||||
| Beta | 4.22 | ||||
| Market Capitalization | 22.47 M | ||||
| Total Asset | 4.78 M | ||||
| Retained Earnings | (66.78 M) | ||||
| Working Capital | 1.61 M | ||||
| Net Asset | 4.78 M |
About Intensity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intensity Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intensity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intensity Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.